Related Experiment Video

Updated: Jun 1, 2026

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
10:01

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

Medical oncology: Patients with brain metastases in early-phase trials

Nicholas F Marko, Robert J Weil

    Nature Reviews. Clinical Oncology
    |May 19, 2011
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis
    07:43

    Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis

    Published on: February 8, 2017

    Modeling Brain Metastases Through Intracranial Injection and Magnetic Resonance Imaging
    06:44

    Modeling Brain Metastases Through Intracranial Injection and Magnetic Resonance Imaging

    Published on: June 7, 2020

    Related Experiment Videos

    Last Updated: Jun 1, 2026

    Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
    10:01

    Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

    Published on: August 2, 2022

    Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis
    07:43

    Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis

    Published on: February 8, 2017

    Modeling Brain Metastases Through Intracranial Injection and Magnetic Resonance Imaging
    06:44

    Modeling Brain Metastases Through Intracranial Injection and Magnetic Resonance Imaging

    Published on: June 7, 2020

    Related Concept Videos

    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    Treatment Resistent Cancers02:56

    Treatment Resistent Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

    Articles linked to this work by shared authors, journal, and citation graph.

    A neurosurgical reappraisal of President Lincoln's fatal cranial injury.

    Neurosurgical review·2025

    Applying brain injury guidelines to patients with traumatic brain injury: A contemporary, consecutive series.

    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia·2025

    Natural language processing augments comorbidity documentation in neurosurgical inpatient admissions.

    PloS one·2024

    Lumbar Decompression With and Without Fusion for Lumbar Stenosis With Spondylolisthesis: A Cost Utility Analysis.

    Spine·2024

    Patterns in Decompression and Fusion Procedures for Patients With Lumbar Stenosis After Major Clinical Trial Results, 2016 to 2019.

    JAMA network open·2023

    Postnatal Myelomeningocele Repair in the United States: Rates and Disparities Before and After the Management of Myelomeningocele Study Trial.

    Neurosurgery·2023

    Beyond cold to hot: oncolytic virotherapy as the next cornerstone of immuno-oncology.

    Nature reviews. Clinical oncology·2026

    Exploring the landscape of targetable alterations in patients with glioblastoma.

    Nature reviews. Clinical oncology·2026

    AI-based augmentation of oncology clinical trials.

    Nature reviews. Clinical oncology·2026

    Clinical toxicity of ADCs and ICI-ADC combinations: mechanisms, patterns and management.

    Nature reviews. Clinical oncology·2026

    De-escalation trials in multiple myeloma: past, present and future.

    Nature reviews. Clinical oncology·2026

    Towards liquid biopsy-based analysis of antitumour immunity.

    Nature reviews. Clinical oncology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us